Nutex Health Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; the filing also provides unaudited fourth-quarter results. Nutex operates hospital facilities and a population health management (PHM) business. The April 1, 2022 reverse business combination with Clinigence means PHM results are included only from the merger date; prior-year comparisons are therefore not fully comparable.
Financial and operating performance
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $219.3 million | $331.5 million |
| Hospital division revenue | $198.5 million | $331.5 million |
| PHM division revenue | $20.8 million | Not included in comparative results |
| Operating income (loss) | $(406.6) million | $170.3 million |
| Net income (loss) attributable to Nutex | $(424.8) million | $132.6 million |
| Adjusted EBITDA (non-GAAP) | $12.5 million | $145.2 million |
| Cash from operating activities | $50.6 million | $173.4 million |
Revenue fell 34% year over year. Hospital revenue declined 40%, reflecting both lower collections and 15% fewer patient visits (161,014 versus 189,016). The company said average insurer payments for emergency-service claims declined approximately 30% after the No Surprises Act took effect, including reductions of up to 37% for physician services. Prior-period revenue also benefited from COVID-related volumes and CARES Act provisions that expired in June 2021.
FY 2022 operating income before corporate and other costs was $13.5 million, versus $179.3 million in 2021. On reported revenue, this represents approximately 6.1% versus 54.1%; the comparison is affected by prior-year COVID-related conditions and the merger’s different reporting scope. Net loss included a $398.1 million non-cash goodwill impairment charge, primarily related to acquired PHM goodwill. Adjusted EBITDA is a company-defined non-GAAP measure and should not be treated as a substitute for GAAP results.
Fourth-quarter 2022 revenue was $53.7 million; operating loss was $5.8 million and net loss attributable to Nutex was $14.8 million, or $0.02 per share. The fourth quarter did not include the goodwill impairment recorded in the third quarter.
Liquidity, debt and balance sheet
- At December 31, 2022, cash and cash equivalents were $34.3 million, down from $36.1 million a year earlier. Current assets were $98.0 million and current liabilities $54.9 million.
- Operating cash flow was $50.6 million, supported in part by $64.3 million from changes in key working-capital accounts. Capital expenditures were $14.6 million; owner and noncontrolling-interest distributions totaled $51.2 million.
- Reported debt was $38.3 million before unamortized issuance costs, including $15.1 million of debt of consolidated real estate entities. The balance sheet separately reports $23.1 million of long-term debt and $12.5 million of current long-term debt, plus $2.6 million of lines of credit.
- Lease liabilities were substantial: approximately $21.1 million operating and $207.8 million financing lease liabilities at year-end. The filing also describes significant future lease payments, much of the finance-lease obligation relating to related parties.
- Nutex had $2.1 million of remaining availability under its existing lines of credit. It was not in compliance with the debt-service-coverage covenant on a term loan with a $1.0 million balance; that balance was classified as current. Management said existing cash, cash equivalents and restricted cash were expected to fund operating and capital needs for at least 12 months, subject to assumptions.
Material changes, outlook and risks
- Merger and reporting scope: The Clinigence combination closed April 1, 2022 and was accounted for as a reverse business combination. Nutex recognized acquired intangible assets and goodwill; the PHM division generated $20.8 million of 2022 revenue and $0.4 million of segment operating income from the post-merger period.
- Goodwill and tax items: The company recorded a $398.1 million non-cash goodwill impairment, revised retrospectively from $408.5 million. The merger also changed Nutex Holdco’s tax status and resulted in a significant non-cash deferred tax charge, among other tax adjustments.
- Regulatory reimbursement exposure: Nutex submitted nearly 28,000 claims to the No Surprises Act independent dispute resolution process in 2022. The process has added administrative workload and delayed collections; outcomes and future reimbursement rates remain uncertain. In Q4, Nutex signed in-network contracts with Provider Network of America providing payment at 300% of Medicare allowable rates for covered members’ services.
- Growth plans: Management planned to open 15–20 hospital facilities by mid-2025, including expansion into Florida, Wisconsin, Ohio and Idaho, and anticipated launching one to three IPAs annually. These are plans, not assured results; management cited funding, staffing, physician recruitment, construction, reimbursement and execution risks.
- Subsequent events: In February 2023, the company closed one micro-hospital and two hospital outpatient departments, estimating $162,000 of severance and $20.5 million of non-cash lease right-of-use asset impairment. It also opened a micro-hospital in Fort Smith, Arkansas.
- Controls and audit: Management and the auditor identified material weaknesses in internal control over financial reporting, including system access, financial-reporting control design and spreadsheet accuracy. The auditor gave an adverse opinion on internal controls, while issuing an unqualified opinion on the financial statements. Management’s remediation work was ongoing.
- Other risks: The filing highlights uncertain out-of-network collections, medical-cost and claims estimates, regulation of physician and related-party arrangements, related-party leases and guarantees, cybersecurity and privacy, and potential dilution from stock issuance. The company had a $100 million, 36-month Lincoln Park equity purchase arrangement but had not sold shares under it at year-end. Large merger-related shareholder lock-ups were scheduled to expire in 2023. No cash dividends were planned.
Important facts for investors to verify
- Whether collections and reimbursement recover as the No Surprises Act dispute process evolves, and the financial impact of the company’s IDR claims and new payer contracts.
- Whether operating cash generation can sustain growth, given the covenant breach, limited credit availability, substantial lease commitments and planned capital needs.
- Whether hospital closures, new openings and the stated expansion timetable affect utilization, profitability and cash requirements; also reconcile the filing’s references to 19 facilities in the business overview and 21 operated locations in its properties disclosure.
- Progress remediating material weaknesses and whether subsequent reporting remains reliable; note the retrospective adjustment to the goodwill impairment amount.
- Potential dilution from the Lincoln Park facility, warrants, options, future stock issuances tied to hospital performance and expiration of merger-related lock-ups.